Palomino Laboratories (PALX) Liabilities and Shareholders Equity (2022 - 2025)

Palomino Laboratories has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $8.4 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $8.4 million, up 6006.17% year-over-year; the trailing twelve-month figure through Dec 2025 was $16.8 million (up 11949.68% YoY), and the FY2025 annual result was $8.4 million, up 6006.17% from the prior year.
• Liabilities and Shareholders Equity came in at $8.4 million for Q4 2025 at Palomino Laboratories, up from $8.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $8.4 million in Q4 2025 to a low of $322.0 in Q2 2024.
• The 4-year median for Liabilities and Shareholders Equity is $500.0 (2022), against an average of $1.5 million.
• Across the five-year window, Liabilities and Shareholders Equity dropped 24.0% in 2023 and soared 2581502.8% in 2025, its largest moves.
• Palomino Laboratories' Liabilities and Shareholders Equity stood at $500.0 in 2022, then decreased by 24.0% to $380.0 in 2023, then jumped by 36248.68% to $138125.0 in 2024, then jumped by 6006.17% to $8.4 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $8.4 million (Q4 2025), $8.3 million (Q3 2025), and $1887.0 (Q2 2025), per Business Quant data.